Enhancing Cellular Function with New Supplements: A Comprehensive Analysis

Feb 25, 2025

40 likes | 108 Views

Explore the impact of Supplemental Figures 3A, 3B, 3C, and 3D on cellular function. This study provides insights into novel supplements' efficacy and benefits for optimizing cellular health. Discover the mechanisms behind these supplements and their potential applications in improving overall well-being.

Share Presentation

Embed Code

Link

supplemental figures
impact
research findings
data interpretation text

amadahy-mitchell

Download Presentation

Enhancing Cellular Function with New Supplements: A Comprehensive Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 3A
Supplemental Figure 3B
Supplemental Figure 3C
Supplemental Figure 3D

Supplemental Figure 1

Supplemental Figure 1. Fig. S1 qRT -PCR analysis of the genes flanking the sbp2’ / sbp2’’ knockouts. All values are given relative to the abundance of transcript observed in P1/7. Data presents the mean from 3 biological replicates. .

106 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Purified Collagens. A). B). Purified Collagen1 ( μ g). 0.12. 0.25. 0.5. 1. 2.5. 5. 10. 20. Purified Col1. Purified Col3. Col1. Purified Collagen3 ( μ g). Col1. 0.12. 0.25. 0.5. 1. 2.5. 5. 10. 20. Col3. Col3. Col1. Col3. Arbitrary Units.

125 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. d-ROM (Carr U). P = 0.0512. recurrence-free period (day). Correlation between d-ROM levels and recurrence-free period in 36 multicentric occurrence cases using linear regression analysis.

89 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1.

84 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Time course of mean arterial pressure, albuminuria, and kidney injury after reduction in renal mass and treatment of C57BL/6 mice with deoxycorticosterone acetate + saline drinking water (DOCA) or treatment of CD-1 mice with hydralazine.

142 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. P-VEGFR2. Tubulin. PlGF-1 250 ng/mL - + + + + Time (min) - 5 10 15 30. B. P-VEGFR2. Tubulin. C.

104 views • 3 slides

Supplemental Figure 5

Supplemental Figure 5. A. MTLn3 GFP-CXCL12. MTLn3 GFP-pQCXIP. C. B. ***. CXCR4. IgG. % of max. BMM Chemotaxis to CXCL12. % of max. CXCR4-PE. CXCR4-PE. IgG. CXCR4. B.

126 views • 1 slides

Supplemental Figure 2

MK-1775. MK-1775 + 37.5 nM MK-8776. MK-1775 + 75 nM MK-8776. MK-1775 + 150 nM MK-8776. MK-1775 + 300 nM MK-8776. Supplemental Figure 2. A. B. HRE cells. fractional proliferation. MK-8776 ( μ M). MK-1775 ( μ M).

117 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. SPERM A -. Sp_D62[A-]. Sp_D62[A+]. SPERM A +. Sp_D62[Tt]. SPERM TOTAL. Sp_D64[Tt]. Sp_D66[Tt]. Sp_P1[Tt]. Sp_D62[SP]. SPERM SPIA. Sp_D64[SP]. Sp_D66[SP]. Sp_P2[SP]. Te_PCl[SP]. TESTES SPIA. Te_PAm[A+]. TESTES Poly (A + ). Te_PCl[A+]. PRM2.

186 views • 6 slides

Supplemental Figure S1

Supplemental Figure S1. A. MDA-MB-231 BCL-2. MCF-7 BCL-2. MDA-MB-231. MCF-7. Bcl-2. Bcl-2. Actin. Actin. B. Supplemental Figure S2. **. *. *. *. *. Control. - - - - - - -. Cisplatin 30 M.

129 views • 6 slides

Supplemental Figure 2

Supplemental Figure 2. Supplemental Figure 2. Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by exogenous HGF on HCC827 cell.

172 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. a. Relative expression. b. Relative expression. c. Relative expression.

112 views • 1 slides

Supplemental Figure 3

108 views • 2 slides

Supplemental Figure 5

Trastuzumab-treated. Control-treated. A. MDA-MB-453. 14.2%. 10.7%. DEAB-inhibited. DEAB-inhibited. B. JIMT-1. 5.2%. 5.4%. DEAB-inhibited. DEAB-inhibited. C. Sum159-HER2. 7.1%. 36%. DEAB-inhibited. DEAB-inhibited. Trastuzumab-treated. Control-treated. D. Supplemental Figure 5.

140 views • 1 slides

Supplemental Figure 2

si RNA #1. si RNA #1. si RNA #1. si RNA #1. si RNA #2. si RNA #2. si RNA #2. si RNA #2. si RNA #3. si RNA #3. si RNA #3. si RNA #3. si control. si control. si control. si control. Casp-9. Casp-2. 47kDa. 51kDa. b -actin. b -actin. Relative mRNA expression. RAIDD. PIDD.

136 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. True leaf from 2 nd to 7 th nodes. (a). M. 1 st (IN) IN. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. PC. ALSV-RNA2. 7. PsEF1- a. 6. 1. 2. 3. 5. True leaf from 2 nd to 7 th nodes. ALSV inoculation. 4. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. 3. Mock. 2.

102 views • 3 slides

Supplemental Figure.

Supplemental Figure. Legend:

96 views • 3 slides

Supplementary Figure 3A

Supplementary Figure 3A. hu_PPARG prom 3 G A C C G C C G C T T G G G G A C C G G G G G A C C G T T C A G C - G A G G G G C G C G C T - - - T 46 ch_PPARG prom 3 G A C C G C C G C G T G G G G A C C G G G G G A C C G T T C A G C - G A G G G G C G C G C T - - - T 46

164 views • 2 slides

Supplementary Figure 3A

A. pFex 33991 bp. Supplementary Figure 3A. B. RPuc-FBR1 4530 bp. Supplementary Figure 3B. C. RP-FBR1 6294 bp. Supplementary Figure 3C.

179 views • 3 slides

Supplemental Figure 3

Supplemental Figure 3.

82 views • 1 slides

Figure I supplemental

Figure I supplemental.

174 views • 6 slides

Supplemental Figure 2

Supplemental Figure 2. a. ADP titration (Clark-type electrode). ~10.00. ~10.27. ~7.01. ~5.11. ~5.00. ~4.03. ADP titration (Seahorse XF24). b. ~3.89. ~3.10. ~2.62. ~2.03. ~1.63. c. Mitochondrial integrity test (Clark-type electrode). d.

121 views • 2 slides

More Related